文献速递青光眼神经眼科

烟酰胺补充与高眼压症患者原发性开角型青光眼

Nicotinamide Supplementation and Primary Open-Angle Glaucoma in Patients With Ocular Hypertension.
PubMed 文献 · JAMA Ophthalmol · 2026-01-01

这项队列研究基于美国67家医疗机构2006至2026年的电子病历数据,经倾向评分1:1匹配纳入2920例高眼压症患者。结果显示,全身烟酰胺暴露与原发性开角型青光眼诊断风险降低相关(HR 0.34;95%CI 0.25-0.47;P<.001),并减少降眼压滴眼液启用和激光小梁成形术需求。

要点

  • 烟酰胺组POAG诊断率为3.5%,对照组为9.0%,绝对风险降低5.5%(95%CI 3.8-7.3)。
  • 烟酰胺组启用一线降眼压滴眼液比例13.6%,对照组21.2%(HR 0.57;95%CI 0.48-0.68;P<.001)。
  • 烟酰胺组激光小梁成形术比例0.8%,对照组1.9%(HR 0.38;95%CI 0.19-0.74;P=.003)。

核心结论

  • 在高眼压症患者中,全身烟酰胺暴露与原发性开角型青光眼诊断风险降低相关。
  • 烟酰胺可能延迟POAG诊断并减少后续药物或激光干预需求,可作为标准治疗的潜在辅助策略。

研究设计与样本

  • 这是一项队列研究,评估美国67家医疗机构联盟2006年3月至2026年3月的去标识化电子病历数据。
  • 以全身烟酰胺补充为唯一预设暴露,采用1:1倾向评分匹配平衡基线协变量。
  • 纳入以高眼压症为主要诊断且至少有一次既往就诊的患者,排除开角型青光眼、激光治疗或青光眼局部用药史者。
  • 匹配后样本共2920例,烟酰胺组与对照组各1460例;烟酰胺组平均(SD)年龄54.4(19.6)岁,女性846例(57.9%);对照组平均(SD)年龄54.9(18.8)岁,女性869例(59.5%)。
  • 平均(SD)随访3.7(1.7)年,采用时间-事件分析估计风险比(HR)及95%CI。

主要发现

  • 烟酰胺组POAG诊断51例(3.5%),对照组132例(9.0%)(HR 0.34;95%CI 0.25-0.47;P<.001)。
  • 烟酰胺队列绝对风险降低5.5%(95%CI 3.8-7.3)。
  • 烟酰胺组启用局部降眼压治疗198例(13.6%),对照组309例(21.2%)(HR 0.57;95%CI 0.48-0.68;P<.001)。
  • 烟酰胺组接受激光小梁成形术12例(0.8%),对照组28例(1.9%)(HR 0.38;95%CI 0.19-0.74;P=.003)。

关键数值与推荐

  • 主要结局为POAG诊断风险,次要结局包括启用一线局部青光眼治疗和需要激光小梁成形术。
  • 烟酰胺暴露定义为有记录的全身烟酰胺使用,对照组无烟酰胺或烟酸使用史。

临床怎么用

  • 对于高眼压症患者,全身烟酰胺补充可能与较低的POAG诊断风险及较少的药物或激光干预相关。
  • 烟酰胺可作为标准治疗的潜在辅助策略,但需进一步前瞻性研究验证。

局限性

  • 原文为基于电子病历数据的回顾性队列研究,可能存在未测量混杂。
  • 烟酰胺暴露依据病历记录,可能存在错分或依从性信息不足。
  • 随访时间平均3.7年,长期结局需更长时间验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ocular hypertension (OHT) is a primary risk factor for primary open-angle glaucoma (POAG), and systemic nicotinamide has emerged as a potential metabolic prophylactic intervention to prevent conversion; however, real-world evidence is lacking. OBJECTIVE: To determine whether systemic nicotinamide supplementation, with potential neuroprotective properties, is associated with reduced risk of POAG diagnosis and delayed need for medical or surgical escalation in patients with OHT. DESIGN, SETTING, AND PARTICIPANTS: This cohort study evaluated deidentified electronic medical record data from a federated research network of 67 US health care organizations between March 2006 and March 2026. Nicotinamide supplementation was the sole exposure of interest and was specified a priori. Propensity score matching (1:1) was used to balance baseline covariates. Patients with a primary diagnosis of OHT and at least 1 prior health care encounter were included, excluding those with history of open-angle glaucoma, laser therapy, or glaucoma topical therapies. EXPOSURES: Documented systemic nicotinamide exposure, compared with a control group having no history of nicotinamide or niacin use. MAIN OUTCOMES AND MEASURES: The primary outcome was risk of POAG diagnosis. Secondary outcomes included initiation of first-line topical glaucoma therapy and requirement for laser trabeculoplasty. Hazard ratios (HRs) and 95% CIs were estimated using time-to-event analyses. RESULTS: The propensity score-matched sample included 2920 patients (1460 in each cohort; nicotinamide group: mean [SD] age, 54.4 [19.6] years, 846 [57.9%] female; control group: mean [SD] age, 54.9 [18.8] years, 869 [59.5%] female). Over a mean (SD) follow-up of 3.7 (1.7) years, POAG diagnosis occurred in 51 patients in the nicotinamide group (3.5%) compared with 132 patients in the control group (9.0%) (HR, 0.34; 95% CI, 0.25-0.47; P < .001), representing an absolute risk reduction of 5.5% in the nicotinamide cohort (95% CI, 3.8-7.3). Topical intraocular pressure-lowering therapy was initiated in 198 patients in the nicotinamide group (13.6%) compared with 309 patients in the control group (21.2%) (HR, 0.57; 95% CI, 0.48-0.68; P < .001). Laser trabeculoplasty was performed in 12 patients in the nicotinamide group (0.8%) vs 28 patients (1.9%) in the control group (HR, 0.38; 95% CI, 0.19-0.74; P = .003). CONCLUSIONS AND RELEVANCE: In this cohort study, systemic nicotinamide exposure was associated with a reduced risk of disease development in patients with OHT. By potentially delaying POAG diagnosis and decreasing the rate of subsequent prescribed interventions, nicotinamide represents a potential adjunctive strategy complementary to standard therapy, warranting further prospective investigation.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Muayad J, Sallam AB, De Francesco T, et al. Nicotinamide Supplementation and Primary Open-Angle Glaucoma in Patients With Ocular Hypertension. JAMA Ophthalmol. 2026. PMID: 42424069. doi:10.1001/jamaophthalmol.2026.2472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。